Science 37, Inc., a Los Angeles-based mobile technology and Virtual Clinical Trial Model startup that focuses on the development of networked patient-centric models for clinical research has raised $31 million in Series B funding led by Redmile Group. Founded in 2014, Science 37 is making the future now with its patient-centered, technology-driven, virtual clinical trial model – from study start-up and patient recruitment, through execution to follow-up.   The company’s proprietary technology platform, NORA ⁽Network Oriented Research Assistant), enables patients to participate in each stage of the clinical trial from the comfort of their own home – including recruitment, informed consent, patient counseling, through to measuring clinical endpoints and potential adverse reactions. The investment will help the startup expand operations and further support development of its novel technology platform that helps accelerate clinical trial research and continue to expand into new therapeutic areas. The traditional clinical trial model is built around trial sites, each of which draws from a local geographic area. Up to 70 percent of potential patients live outside of these local areas. Science 37 replaces physical sites with a single “metasite™” and brings the clinical trial directly to the patient’s home. This means that the patient is allowed to retain their existing doctor while benefiting from reduced travel time and access to quality healthcare via telemedicine or doctor home visits when appropriate.